---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-339292"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2026-08-07T12:45:14+00:00"
generated_at: "2026-08-07T12:50:10.469568+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atossa Q2 2026: OpEx $8.7M, R&D $4.9M; raises up to $16.5M from offering

## Summary
- Total operating expenses $8.7M in Q2 2026, down $0.3M from $9.0M in Q2 2025.
- R&D expenses $4.9M in Q2 2026, down 11% YoY on lower preclinical spend.
- G&A expenses $3.8M, up 7% YoY, driven by higher legal fees from settled patent litigation.
- Raised $4.5M upfront plus up to $12M from Series A/B warrant exercises to fund (Z)-endoxifen.
- Presented (Z)-endoxifen data at ASCO/AACR; EVANGELINE Phase 2 enrollment completed as of June 30, 2026.

## SEC filing metadata
- accession: 0001193125-26-339292
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2026-08-07T12:45:14+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312526339292/0001193125-26-339292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312526339292/atos-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-339292
- JSON: https://secwatch.observer/filing/0001193125-26-339292.json
- Plain text: https://secwatch.observer/filing/0001193125-26-339292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.